#1 Clinical Trials Search in Europe

Allogeneic Placenta-Derived Decidual Stromal Cells, Ex-Vivo Expanded

This article delves into the use of Allogeneic Placenta-Derived Decidual Stromal Cells, Ex-Vivo Expanded, in clinical trials for treating steroid-resistant severe acute Graft-vs-Host Disease (GvHD). This innovative cell therapy is being studied to assess its safety, efficacy, and potential benefits for patients who have undergone hematopoietic stem cell transplantation and developed this challenging complication.

Table of Contents

What are Decidual Stromal Cells?

Allogeneic placenta-derived decidual stromal cells (DSCs) are a type of cell therapy being studied for the treatment of various medical conditions. These cells are obtained from the decidua, which is a specialized layer of the uterus that forms during pregnancy[1]. The term “allogeneic” means that the cells come from a donor rather than the patient themselves.

In this context, DSCs are being investigated as a potential treatment for a serious complication that can occur after stem cell transplantation called steroid-resistant acute graft-versus-host disease (SR-aGvHD).

Target Condition: Steroid-Resistant Acute Graft-versus-Host Disease

Graft-versus-host disease (GvHD) is a condition that can occur after a person receives a stem cell transplant from a donor. In this condition, the donor’s immune cells attack the recipient’s tissues, causing various symptoms and complications[1].

Acute GvHD (aGvHD) is a form of GvHD that typically occurs within the first 100 days after transplantation. When aGvHD does not respond to standard treatment with high-dose corticosteroids, it is called steroid-resistant acute GvHD (SR-aGvHD). This condition is particularly challenging to treat and can be life-threatening[1].

How the Treatment Works

Decidual stromal cells are believed to have immunomodulatory properties, meaning they can help regulate the immune system. When administered to patients with SR-aGvHD, these cells may help to:

  • Reduce inflammation
  • Modulate the immune response
  • Promote tissue repair

The treatment is given as an intravenous infusion, which means it is delivered directly into the bloodstream through a vein[1].

Clinical Trial Details

A phase II clinical trial is currently underway to evaluate the safety and effectiveness of DSCs for treating SR-aGvHD. Here are some key details about the trial:

  • It is a multicenter, open-label, randomized study[1].
  • The trial compares DSCs to the best available treatment (BAT) for SR-aGvHD[1].
  • The main objectives are to assess the safety of DSCs and measure the durable overall response rate at 56 days after treatment[1].
  • Participants must be 18 years or older and have been diagnosed with steroid-resistant acute GvHD after receiving a stem cell transplant[1].

Potential Benefits

If successful, this treatment could offer several potential benefits for patients with SR-aGvHD:

  • Improved response rates compared to current treatments
  • Reduced need for long-term steroid use
  • Better overall survival rates
  • Improved quality of life for patients after stem cell transplantation

Safety Considerations

As with any new treatment, safety is a primary concern. The clinical trial is designed to carefully monitor for any side effects or complications. Some potential risks that are being evaluated include:

  • Infusion-related reactions
  • Infections
  • Potential interactions with other medications

It’s important to note that patients with certain conditions are excluded from the trial to ensure their safety. These include people with active uncontrolled infections, severe heart or lung disease, and certain other medical conditions[1].

Conclusion

Allogeneic placenta-derived decidual stromal cells represent a promising new approach to treating steroid-resistant acute graft-versus-host disease. While the treatment is still in the clinical trial phase, it offers hope for patients who have not responded to standard therapies. As research continues, we may learn more about the potential benefits and risks of this innovative cell therapy.

Aspect Details
Study Type Phase II clinical trial, multicenter, open-label, randomized
Treatment Allogeneic Placenta-Derived Decidual Stromal Cells, Ex-Vivo Expanded
Condition Steroid-resistant severe acute Graft-vs-Host Disease (GvHD)
Primary Objectives Assess safety, tolerability, and durable overall response rate at Day 56
Key Inclusion Criteria Adults 18+, post-HSCT, Grade II-IV acute GvHD, steroid-resistant
Key Exclusion Criteria Active uncontrolled infections, severe organ dysfunction, recent malignancies
Primary Endpoints Adverse events, durable overall response rate at Day 56
Secondary Endpoints Overall survival, non-relapse mortality, infection rates, quality of life

FAQ

  • What is Graft-vs-Host Disease (GvHD)? Graft-vs-Host Disease is a complication that can occur after a stem cell or bone marrow transplant. It happens when the donor's immune cells (the graft) attack the recipient's body (the host), causing inflammation and damage to various organs.
  • What are Allogeneic Placenta-Derived Decidual Stromal Cells? These are specialized cells derived from the placenta of a donor (allogeneic means from another person). They are expanded in the laboratory (ex-vivo) and have potential therapeutic properties, particularly in modulating the immune system.
  • How are these cells being used in the clinical trial? The cells are being tested as a treatment for patients with steroid-resistant severe acute GvHD. They are compared to the best available treatment to assess their safety and effectiveness in managing this condition.
  • What is the main goal of the clinical trial? The main objectives are to assess the safety and tolerability of the decidual stromal cells and to measure the durable overall response rate at 56 days after treatment in patients with steroid-resistant severe acute GvHD.
  • Who can participate in this clinical trial? The trial is open to adults (18 years or older) who have undergone a stem cell transplant, developed Grade II to IV acute GvHD, and have not responded adequately to high-dose steroid treatment. There are specific inclusion and exclusion criteria to ensure patient safety and study validity.

Ongoing Clinical Trials on Allogeneic Placenta-Derived Decidual Stromal Cells, Ex-Vivo Expanded

  • Study on the Safety of Decidua Stromal Cells for Patients with Steroid-Resistant Severe Acute Graft vs Host Disease

    Not recruiting

    1 1
    Investigated drugs:
    Denmark Norway Sweden

Glossary

  • Graft-vs-Host Disease (GvHD): A complication following stem cell or bone marrow transplantation where the donor's immune cells attack the recipient's body tissues.
  • Allogeneic: Referring to cells or tissues that come from a genetically different donor of the same species.
  • Decidual Stromal Cells (DSC): Specialized cells derived from the decidua, the lining of the uterus during pregnancy, which have potential immunomodulatory properties.
  • Ex-Vivo Expanded: Cells that have been grown and multiplied outside the body in laboratory conditions.
  • Hematopoietic Stem Cell Transplantation (HSCT): A procedure that replaces damaged or diseased bone marrow with healthy stem cells, which can develop into new blood cells.
  • Steroid-Resistant: A condition that does not respond adequately to treatment with steroid medications.
  • Overall Response Rate (ORR): The proportion of patients whose disease improves with treatment, including both complete and partial responses.
  • Non-Relapse Mortality (NRM): Deaths occurring after treatment that are not due to the return or progression of the original disease.
  • Calcineurin Inhibitors (CNI): A class of immunosuppressive drugs often used to prevent or treat GvHD.
  • Quality of Life (QoL): A measure of an individual's overall well-being and ability to function in daily life.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-of-decidua-stromal-cells-for-patients-with-steroid-resistant-severe-acute-graft-vs-host-disease/